Psychosomatics
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Bondurant, T.
* Articles by El Mallakh, R. S.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Bondurant, T.
* Articles by El Mallakh, R. S.
Related Collections
* Antidepressants
Psychosomatics 39:296-298, June 1998
© 1998 The Academy of Psychosomatic Medine


Letter

Effect of Fluoxetine on Prothrombin Time

Timothy Bondurant, M.D., Maria Judith Darrell, M.D., Sherif El Asyouty, M.D., William R. Hartman, M.D., Bryan Jones, M.D., Peter M. Steiner, M.D., Kathy M. Vincent, M.D., Xiao-ping Li, M.D., Mary O. Huff, Ph.D., and Rif S. El Mallakh, , M.D., Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Kentucky

Key Words:

TO THE EDITOR: Several cases of increased bleeding complications in patients receiving serotonin reuptake inhibiting (SRI) antidepressants and anticoagulant therapy have been reported.13 While some investigators have argued that this side effect may be caused by the action of SRI agents on the serotonergic system of platelets,4 the actual mechanism of the interaction remains unknown.

It is possible that SRIs may interfere with the coagulation cascade directly. To investigate this possibility, we examined the effect of increasing concentrations of fluoxetine on prothrombin time (PT) ex vivo in the blood of five normal volunteers. The results (Figure 1) show that fluoxetine does not appear to affect PT in concentration ranges usually achieved in routine clinical use (10–1,000 mg/ml).5 At a very high fluoxetine level (100,000 mg/ml), PT is significantly increased above baseline (16.6 ± SD 2.03 vs. 12.3 ± 1.10 sec, t=-8.45, P<0.001). However, this level of fluoxetine also hemolyzes blood cells, a process that could artificially elevate PT.



View larger version (29K):
[in this window]
[in a new window]
 

Figure 1. Prothrombin time as a function of whole blood concentration of fluoxetine



These data suggest that fluoxetine does not alter PT. However, we did not investigate the effects of its metabolite, norfluoxetine, nor of other SRIs that may also contribute to bleeding problems.

REFERENCES

  1. Aranth J, Lindberg C: Bleeding, a side effect of fluoxetine (letter). Am J Psychiatry 1992; 49:412
  2. Calhoun JW, Calhoun DD: Prolonged bleeding time in a patient treated with sertraline (letter). Am J Psychiatry 1996; 153:443
  3. Skop BP, Brown TM: Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37:12–16[Abstract/Free Full Text]
  4. Alderman CP, Moritz CK, Ben-Tovim DI: Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmachother 1992; 26:1517–1519
  5. Koran LM, Cain JW, Dominguez RA, et al: Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Am J Psychiatry 1996; 153:1450–1454[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Arch Intern MedHome page
S. O. Dalton, C. Johansen, L. Mellemkjaer, H. T. Sorensen, B. Norgard, and J. H. Olsen
Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Tract Bleeding: A Population-Based Cohort Study
Arch Intern Med, January 13, 2003; 163(1): 59 - 64.
[Abstract] [Full Text] [PDF]


Home page
Acad. PsychiatryHome page
R. S. El-Mallakh
A Novel Residents' Research Seminar
Acad Psychiatry, March 1, 2001; 25(1): 57 - 60.
[Abstract] [Full Text]


Home page
PsychosomaticsHome page
W. W. Shen, C. M. Swartz, and J. W. Calhoun
Is Inhibition of Nitric Oxide Synthase a Mechanism for SSRI-Induced Bleeding?
Psychosomatics, June 1, 1999; 40(3): 268 - 269.
[Full Text]


This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Bondurant, T.
* Articles by El Mallakh, R. S.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Bondurant, T.
* Articles by El Mallakh, R. S.
Related Collections
* Antidepressants


Get information about faster international access.

Privacy Policy

Copyright © 1998 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. Academy of Psychosomatic Medicine
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org